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Abstract:  Introduction: Ostene® is a water-soluble wax-like alkylene oxide 
copolymer preparation for use as a mechanical hemostatic agent. This study 
aims to evaluate the effects of Ostene® on bone healing. Materials and Methods: 
Twenty albino rabbits were divided into four groups according to post-treatment 
follow-up (24 hr, 3 days, 7 days, 14 days) with five rabbits in each group. Each 
rabbit in all groups was treated with two study materials (Ostene® and Gelfoam®). 
Three holes were made in the mandibular bone of each rabbit using 5mm surgical 
bur; two holes were made on right side: one for testing Ostene® and another for 
Gelfoam®. A third hole, on the left side of mandible, was not treated, and was 
used as a control. Finally, the incision was closed. The specimens were collected 
at different days post-treatment and examined by histopathology. Result and 
Discussion: This study showed that there is a significant difference (p-value≤ 
0.05) between the Ostene® group and the other groups (Gelfoam® and control). 
At 24 hr post intervention, there is a significant difference in osteoblast cell 
formation (p-value=0.03), and osteoclast cell formation (p-value=0.05). New 
blood vessel formation, osteoblast and osteoclast cell formation for Ostene® group 
at 3 days post-intervention were also significantly different (p-values = 0.05, 0.03, 
0.04, respectively). At 7 days post-intervention p-values were 0.05 for osteoblast 
formation and 0.04 for osteoclast formation, respectively. After 14 days of healing 
p-value for osteoblast cell formation in the Ostene® group was 0.05 and 0.04 for 
osteoclast cell formation. Conclusions: The bone hemostatic agent Ostene® is an 
effective at enhancing osteogenesis by initiating proliferation of osteoblast and 
osteoclast cells.
Keywords: Bone hemostatic agent; ostene; alkylene oxide copolymer; water 
soluble wax; wound healing.
INTRODUCTION.
Bone is a complex, highly organized and specialized connective 
tissue. It is a unique tissue that is healed by regeneration rather than 
repair. Bone healing consists of three overlapping phases. The first 
one is an inflammation process that starts immediately after trauma. 
There is an invasion of inflammatory cells, hematoma formation, and 
mesenchymal cells migration occurs. Granulation tissue formation is 
initiated by fibroblasts and mononuclear cells, which then matures to 
connective tissue that later converts to cartilage. Cartilage becomes 
woven bone by a process of mineralization, is then replaced by cortical 
bone and the medullary cavity is restored. After that, the remodeling 
process of the bone is started which is a slow process that occurs over 
months and years; adequate bone strength is typically achieved in 3-6 
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months.1-4  During surgery that involves bone, bleeding 
can be controlled with suitable hemostatic agents. The 
choice of a suitable hemostatic agent and the time 
of its application require full consideration of their 
mechanisms of action, efficacy and possible adverse side 
effects.5 Currently, many hemostatic agents are available; 
Ostene® is one of the most effective and easy to use 
material. Ostene® is an alkylene oxide copolymer wax-
like preparation, a kind of water-soluble wax (WSW), 
and cranial and spinal surgeries were the first to use it.6 
Many studies have shown that Ostene® is a biocompatible 
and absorbable hemostatic agent. It induces immediate 
hemostasis by creating a mechanical and physical barrier 
but does not act at a biochemical level.7,8 In 2001 Wang 
et al.,8 firstl described the use of Ostene® as alternative 
to bone wax. The authors found that Ostene® did not 
inhibit bone growth, while achieving hemostasis. In 
other studies it was found that Ostene® is a hydrophilic 
and water soluble material, it does not interfere with 
coagulation and it is considered a bio-inert material. It 
is eliminated from the body unchanged through renal 
clearance within 48 hr,9,10  but it is an expensive.11 It 
is approved by the Food and Drug Administration as 
a water soluble implant material indicated for use in 
the control of bleeding of bone surfaces.12 Gelfoam® 
is a water-insoluble, off-white, non-elastic, porous, 
malleable hemostatic agent prepared from purified 
porcine skin gelatin. It can absorb up to 45 times its 
weight of blood.13 The hemostatic effect of Gelfoam® 
is a physical process rather than having a direct effect 
on the clotting cascade.14 Gelfoam® has the ability of 
swelling more than collagen or cellulose and can double 
its volume, and although this swelling provides a good 
mechanical hemostatic action it is considered a negative 
characteristic, particularly when used near nerves as it 
causes compressive problems. Gelatin foam is absorbed 
within 4 to 6 weeks, and although it is derivative of 
animal products, it is non-antigenic.15 Gelfoam® can be 
applied either as a dry sponge, moistened with sodium 
chloride solution, or saturated with topical purified 
thrombin.16 The drawbacks of using gelatin include 
an increased rate of infection, granuloma formation, 
fibrosis, and the potential for breaking the clot if the 
sponge is removed.17
MATERIALS AND METHODS.
This work has been approved by the appropriate 
ethical committees related to the institution in which it 
was performed, and animal care was in accordance with 
institution guidelines. Ostene® (alkylene oxide copolymer) 
was provided by Ceremed Inc., and Gelfoam® was 
purchased from SEPTODONT. 
Experimental Model: Twenty 6-8 months old male 
albino rabbits were used, each weighing about 2.3±0.5kg. 
The animals were housed in an animal facility organized 
for that purpose, fed a normal diet and water ad libitum. 
Each individual animal was given an intramuscular dose of 
ketamine hydrochloride 4mg/kg in 50mg/ml and xylazine 
base 5mg/kg in 20mg/ml,18 injected into the thigh muscle. 
After 10-15 minutes, anesthetic integrity was checked by 
testing loss of the ear pinch reflex.19
Experimental groups
Twenty albino rabbits were divided into four 
groups according to sacrificing days post-intervention, 
corresponding to follow-up periods (24 hr, 3 days, 7 days, 
14 days), with five rabbits per group. Every rabbit in all 
groups was treated with both study materials (Ostene® and 
Gelfoam). Three holes were made in the mandibular bone 
of each rabbit using a 5mm surgical bur; two holes were 
made on the right side: one for testing Ostene® and another 
for Gelfoam®. A third hole, on the left side of mandible, was 
not treated, and was used as a control.
Group 1: 24 hr, Ostene, Gelfoam, and no material control.
Group 2: 3 days, Ostene, Gelfoam, and no material control.
Group 3: 7 days, Ostene, Gelfoam, and no material control.
Group 4: 14 days, Ostene, Gelfoam, and no material control.
Surgical procedure and post-operative care
   With aseptic surgical technique the animals underwent 
submandibular incision, the surgical site was exposed 
(mandibular bone), then two holes were made on the 
right side and a third hole on left side of mandible using 
a 5mm surgical bur, and appropriate study materials were 
applied. Finally the incision was closed using VICRYL® 
coated polyglactin suture 3-0. A single dose of 5mg/kg of 
the antibiotic oxytetracycline was injected intramuscular 
immediately post operatively.20 The operated animals were 
separately caged until full recovery from anesthesia. The 
operated animals were closely observed during first twenty 
four hours post-operatively, particularly regarding their 
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feeding and physical activity. All animals began their 
normal activities and eating within 3-4 hr postoperatively.
After completing the given healing period, the animals 
were sacrificed and the mandible was dissected and 
stored in 10% formalin for fixation. The mandible of 
each group was divided into three pieces according to 
the material used (Ostene®, gelfoam and control). The 
bone specimens were then decalcified in 10% formic 
acid and 10% hydrochloric acid. After decalcification, 
the specimens were dehydrated through graded series of 
ethanol and xylene (70-99%), then embedded in paraffin 
wax, sectioned by microtome (4µm thickness) and stained 
using hematoxylin and eosin.
Histological Criteria
   To assess the speed of healing, we used criteria according 
Lucaciu et al.,21 with some modifications as follows:
A. Amount of granulation tissue
1. Profound | 2. Moderate | 3. Scant | 4. Absent
B. Amount of inflammatory infiltration
1. Plenty | 2. Moderate  | 3. Few  | 4. Absent
C. Neo-formation of blood vessel
0. Absent | 1. Present at peripherally | 2. Present at centrally| 
3. Present at peripherally and centrally
D. Presence of osteoblast
0. Absent | 1.Present at peripherally | 2.Present at centrally| 
3.Present at peripherally and centrally
E. Presence of osteoclast
0. Absent | 1. Present at peripherally | 2. Present at centrally| 
3. Present at peripherally and centrally
Histopathological examinations were done by using 
light microscope, Olympus (at X40, X10,) and read by two 
expert histopathological examiners separately. The final 
score was the mean values of the two readings.
Statistical Analysis: The data were processed statistically 
using the SPSS version 21 for Windows 10 pro, Lenovo 
laptop think pad L460. The associations between variables 
for histological analysis were analyzed using Friedman NPar 
Test for comparing the differences between groups within 
same period, Wilcoxon Signed-Rank Test for determining 
the group that led to differences within the same period.
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Figure 1.  Histological analysis of bone healing in mandible defects. Representative images at 3 days after surgery. 
H&E staining demonstrates osteoblasts (red arrow), and osteoclast (green arrow), and new blood vessel (yellow arrow) 
in the alkylene oxide copolymer (Ostene)-treated defects.
A. With mostly fibrous tissue (white arrows)  observed at the site of the gelfoam. B. Control treated defects. C. Low magnification (x10, left) and high magnifica-
tion (x40, right) are shown.
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                                                               Mean rank and p-values of  Friedman Test for Histopathological readings
Periods Variables  Inflammation Granulation new Blood     formation Osteoclast 
   tissue vessel formation Osteoblast formation 
24 hrs Ostene 1.20 1.80 2.80 2.60 2.20
 Gelfoam 2.30 1.40 2.00 2.20 2.20
 Control 2.50 2.80 1.20 1.20 1.60
 p-values 0.038* 0.039* 0.041* 0.047* 0.449
3 days Ostene 1.20 1.60 2.40 2.90 2.70
 Gelfoam 2.10 2.20 2.40 1.70 1.80
 Control 2.70 2.20 1.20 1.40 1.50
 p-values 0.042* 0.135 0.032* 0.015* 0.039*
7 days Ostene 1.90 1.80 2.40 2.70 2.70
 Gelfoam 2.20 1.80 2.20 2.10 2.10
 Control 1.90 2.40 1.40 1.20 1.20
 p-values 0.368 0.264 0.211 0.022* 0.035*
14 days Ostene 3.00 2.00 2.10 2.30 2.80
 Gelfoam 1.50 2.00 2.20 2.60 2.10
 Control 1.50 2.00 1.70 1.10 1.10
 p-values 0.007* . 0.678 0.025* 0.014*
                    Wilcoxon signed rank-test for histopathological readings between variables
 within same period
Periods Histopathological Readings   Variables
  Ostene-gelfoam Ostene-control Gelfoam-control
24 hr Inflammation 0.06 0.06 0.2
 Granulation tissue 0.2 0.1 0.03*
 New blood vessel formation 0.1 0.03* 0.1
 Osteoblast formation 0.2 0.05* 0.04*
 Osteoclast formation  p-value = 0.4 in Friedman test
3 days Inflammation 0.05* 0.04* 0.07
 Granulation tissue  p-value = 0.1 in Friedman test
 New Blood vessel formation 1.00 0.05* 0.06
 Osteoblast formation 0.05* 0.03* 0.3
 Osteoclast formation 0.08 0.04* 0.3
7 days Inflammation  p-value = 0.3 in Friedman test
 Granulation tissue  p-value = 0.2 in Friedman test
 New Blood vessel formation  p-value = 0.2 in Friedman test
 Osteoblast formation 0.1 0.05* 0.05*
 Osteoclast formation 0.4 0.04* 0.1
14 days Inflammation 0.03* 0.03* 1.00
 Granulation tissue  p-value =(.) in Friedman test 
 New Blood vessel formation  p-value = 0.6 in Friedman test
 Osteoblast formation 1.00 0.05* 0.03*  
 Osteoclast formation 0.1 0.04* 0.05*
Table 1. Mean rank and p-values of Friedman Test for histopathological readings.
Table 2. Wilcoxon signed-rank test for histopathological readings between variables within same period.
*statistical significant result p≤ 0.05   
*statistical significant result p≤ 0.05   
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RESULTS.
The results of the analysis of the differences 
between the two study materials and control regarding 
inflammation, granulation tissue formation, blood vessel 
formation, and osteoclast and osteoblast formation, at 
given time periods of healing are shown in Table 1. 
Wilcoxon signed-rank test revealed the differences 
between ostene-gelfoam, ostene-control, and gelfoam-
control for all periods of healing as shown in Table 2. 
Statistical significance was set at p-value ≤0.05
DISCUSSION.
Bleeding from the defects treated with Ostene® 
completely ceased shortly after its application compared 
to the defects treated with gelfoam and control. This 
observation is in agreement with other studies, wehre 
it was found that Ostene® formed a mechanical barrier 
that prevents the flow of blood from the exposed 
bone.9,22 Handling of Ostene® material compared to 
gelfoam was more favorable, as it was stuck more to the 
bone. Furthermore, Ostene could be better reshaped 
to match the size of defect. This study was designed to 
histopathologicaly compare the effect of Ostene® and 
gelfoam on bone healing. To our knowledge, the data 
in this report is one of few reports comparing the two 
materials, so more research is still needed. Our results 
show that Ostene® has an obvious effect on bone healing, 
and if it does not accelerate the healing process, it does 
not delay it either. We believe that this is because Ostene® 
does not aid the development of infection, which agrees 
with Wellisz et al.,9 who reported that the bone healing 
process was not affected by the presence of Ostene® and 
it did not induce infection.23 Regarding inflammatory 
infiltrations during the first 24 hr of healing, there was 
no significant difference between the three groups. 
This further indicates that Ostene® did not impair 
the healing process, in agreement with the study of 
Vestergaard et al.,22 in which they explained this effect 
by a reduction in cellular response to Ostene®, probably 
due to the quick elimination time. At 3 days post-
intervention, there were significant differences between 
Ostene® and both gelfoam and control groups in the 
induction of inflammation. The number of inflammatory 
cells at 3 days post-intervention in the Ostene® group 
was higher and more specific with a high capacity for 
secreting more chemotactic factors, the process during 
the first 3 days appeared faster, and healing appear to 
take a shorter time in comparison with the other groups. 
As Ostene® is absorbed within 48 hr,24 at  7 days 
post-intervention it had disappeared and its effect had 
thus subsided, nonetheless the healing process and 
inflammatory response appeared better in Ostene® group 
as compared to gelfoam at 14 days of bone healing, as 
gelfoam may act as a mesh for entrapping bacteria; this 
may lead to abscess formation.25,26 Regarding granulation 
tissue formation, statistically our result showed there 
was no significant differences between Ostene® and the 
other groups (gelfoam and control) along all the periods 
of healing. This may be because Ostene® has no direct 
effect on fibroblast cells or that the amount of Ostene® 
applied into the defect was not sufficient to produce 
an obvious effect on the establishment of granulation 
tissue, or that Ostene® dissolved too quickly. According 
to a study of Claes et al.,27 in larger defect sizes (≥6mm) 
a large amount of connective tissue formation is seen.
Because the size of the defect in our study was 
small (5mm), this may explain why the granulation 
tissue was not seen clearly. A study by Gurcan et al.,28 
showed Ostene® had antifibrosis effect. This finding is in 
agreement with our results. Despite we showed no effect 
of Ostene® in granulation tissue formation, its effect on 
the initiation of osteoblast, osteoclast proliferation and 
new blood vessels formation was clear in histological 
examination. 
Hence, Ostene® has an effect when compared with the 
other groups (gelfoam, control) considering osteoblast 
and osteoclast cells formation at 3 days post-intervention, 
as illustrated by the significant difference observed in 
formation of these types of cells. These findings agree 
with several studies in which Ostene® was found to be 
as absorbable as bone wax but without adverse effects on 
bone healing or osteogenesis.6,29-31
 CONCLUSION.
Ostene® bone hemostatic agent is an effective agent 
that does not inhibit bone healing and enhances 
osteogenesis by initiating proliferation of osteoblast and 
osteoclast cells.
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